Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Bloomberg Customers

Markets & Finance

Bear Stearns Cuts Genzyme to Peer Perform

Bear Stearns cut Genzyme (GENZ) to peer perform from outperform, citing Medicare's plans to dramatically cut reimbursement for the company's product Synvisc in 2006.

Analyst Mark Schoenebaum says that under the new medicare "J-code" all hyaluronic acid derivatives will be reimbursed at $7.20 per milogram. Accordingly, 2006 reimbursement rates for Synvisc will fall by 42%, while competitors' rates will rise. He estimates that Genzyme's earnings per share could be reduced by 6 cents to 16 cents in 2006 because of the falling Synvisc reimbursement rate. While he believes the earnings per share impact of the declining reimbursement will likely be incremental rather than catastrophic, he says the increased uncertainty warrants a downgrade.

blog comments powered by Disqus